Nureca Ltd Q2FY26 Results: From Pandemic Darling to Wellness Phoenix—3.6 Cr Profit, 856% Jump, and a Buyback That Says “We’re Still Alive!”

1. At a Glance

If COVID made “oxygen saturation” a household phrase, Nureca Ltd (₹295/share, market cap ₹295 crore) made it a home appliance. The digital-first health gadget maker that once sold pulse oximeters faster than onions in 2020 is back with a vengeance. Q2FY26 results show a profit of ₹3.63 crore, up 856% YoY, on sales of ₹37.74 crore (up 21%). Yeah, you read that right — a company that was once deep in the red just rediscovered green ink.

With a P/E of 71.9, it’s not cheap, but at least this time the “E” isn’t zero. Operating margins are still humble at 8.66%, but compared to the company’s earlier adventures in negative OPM territory, it’s like watching a phoenix crawl before flying.

Promoters hold 65%, FIIs nibble at 0.07%, and the public owns the rest. Debt is nearly nonexistent at ₹5.39 crore, and a fresh buyback of ₹19.14 crore at ₹330/share just got approved — a bold move that says, “Yes, we’re smaller, but we’re serious.”

Still, can the company sustain profits beyond one quarter of quick-commerce miracles? Let’s find out.

2. Introduction

Once upon a pandemic, every Indian household suddenly needed a pulse oximeter, a nebulizer, and a digital thermometer. That’s when Nureca Ltd, born in 2016, became the darling of home healthcare. Their brands like Dr. Trust and Dr. Physio became as common as Dettol and Dabur. But when COVID went on vacation, so did their profits.

By FY23 and FY24, margins turned negative, sales shrunk, and investors wondered if “Dr. Trust” was just a metaphor for misplaced faith. Yet, FY25 and Q1–Q2FY26 changed the tone. Revenue climbed, profitability returned, and the board began to flex financial muscles with a buyback announcement.

Now, with 277+ SKUs, new launches in wellness devices and connected health gadgets, and lightning-fast deliveries via Blinkit and Swiggy, Nureca seems determined to reinvent itself as India’s fitbit-friendly pharma alternative.

But can a once-hot pandemic stock thrive in the calmer world of preventive wellness? Or is this a classic “dead cat bounce” disguised in gym clothes? Strap in, dear reader — this will be more entertaining than your morning yoga session.

3. Business Model – WTF Do They Even Do?

Nureca makes and sells home healthcare and wellness products under multiple brands. It’s basically the love child of Croma’s healthcare aisle and your mom’s medical cabinet.

Their portfolio covers:

• Chronic care devices – blood pressure monitors, glucometers, thermometers.
• Lifestyle gadgets – massagers, humidifiers, and personal scales for those chasing fitness or fighting Delhi winters.
• Orthopedic care – pain relief cushions, massagers, heating pads, and memory foam pillows.
• Mother & baby – from bottle warmers to carry cots under the brand Trumom.
• Nutrition and supplements – because who doesn’t want capsules that promise more energy and less guilt.
• Connected devices – app-linked ECGs, smart scales, and BP monitors integrated with the Dr. Trust 360 app.

What makes Nureca spicy is its digital-first sales model. About 93% of its Q1FY26 sales came online, with only 7% from offline distribution. The company lists on quick-commerce apps like Zepto, Swiggy, and Blinkit, making it possible to get a nebulizer faster than a pizza.

With over 192 distributors, 22,000 retail touchpoints, and a newly approved manufacturing plant in Punjab, Nureca is turning from an e-commerce importer to a Made-in-India healthcare manufacturer.

4. Financials Overview

Quarterly Results – Consolidated Figures in ₹ Crores

Commentary:
From a negative EBITDA company to posting 8.66% operating margins, Nureca just pulled a gym-mirror transformation. The ₹3.63 crore PAT, though